JAHA:慢性阻塞性肺疾病对射血分数正常心力衰竭患者的影响

2021-11-21 MedSci原创 MedSci原创

大约七分之一的射血分数正常的心力衰竭患者伴有COPD,这与更大的功能受限和心力衰竭住院和死亡的风险更高相关。

关于慢性阻塞性肺疾病(COPD)对射血分数正常的心力衰竭(HFpEF)患者的影响知之甚少。

近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员在血管紧张素受体阻滞剂与血管紧张素受体阻滞剂在射血分数正常的心力衰竭中的总体结果的前瞻性比较(PARAGON-HF)试验中,根据COPD状态检查了射血分数正常的心力衰竭患者的结局。该研究的主要结局包括心力衰竭和心血管死亡的首次和反复住院的复合结局。

在4791名患者中,670名(14%)患有COPD。COPD患者更可能是男性(58% vs. 47%;P<0.001),纽约心脏协会功能分级更差(III/IV级24% vs. 19%),堪萨斯城心肌病问卷临床总结评分更差(69 vs. 76;P<0.001)和更频繁的心力衰竭住院史(54% vs. 47%;P<0.001)。堪萨斯城心肌病问卷临床总结评分与COPD的下降幅度大于其他常见合并症。

与没有COPD的患者相比,COPD患者的超声心动图显示右心室扩大、血清肌酐升高(100μmol/L vs. 96μmol/L)和中性粒细胞与淋巴细胞比率(2.7 vs. 2.5)增大。多变量调整后,COPD与较差的结局相关:主要结局的调整后比率为1.51(95%CI为1.25–1.83),总心力衰竭住院率为1.54(95%CI为1.24–1.90),心血管死亡(调整后的风险比)[HR]为1.42;95%CI为1.10-1.82)和全因死亡(调整后的HR为1.52;95%CI为1.25-1.84)。与其他合并症相比,COPD与更差的患者结局相关,并且堪萨斯城心肌病问卷临床总结评分在COPD患者中比没有患者下降得更多。

由此可见,大约七分之一的射血分数正常的心力衰竭患者伴有COPD,这与更大的功能受限和心力衰竭住院和死亡的风险更高相关。

原始出处:

Leanne Mooney,et al.Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF.JAHA.2021.https://www.ahajournals.org/doi/full/10.1161/JAHA.121.021494

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696993, encodeId=5ea6169699325, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 19 04:12:43 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944298, encodeId=2bd419442984d, content=<a href='/topic/show?id=86a946809a5' target=_blank style='color:#2F92EE;'>#射血分数正常心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46809, encryptionId=86a946809a5, topicName=射血分数正常心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Aug 14 06:12:43 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994321, encodeId=220d199432164, content=<a href='/topic/show?id=b67646808b9' target=_blank style='color:#2F92EE;'>#射血分数正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46808, encryptionId=b67646808b9, topicName=射血分数正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Mar 02 11:12:43 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268689, encodeId=1a4e1268689dc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Nov 23 03:12:43 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072538, encodeId=debc10e253850, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Nov 21 16:34:18 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072528, encodeId=680010e25284c, content=好极了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00ed5697300, createdName=ms6000001024089719, createdTime=Sun Nov 21 16:06:05 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072487, encodeId=3f9e10e2487b9, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Nov 21 12:22:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
    2022-01-19 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696993, encodeId=5ea6169699325, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 19 04:12:43 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944298, encodeId=2bd419442984d, content=<a href='/topic/show?id=86a946809a5' target=_blank style='color:#2F92EE;'>#射血分数正常心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46809, encryptionId=86a946809a5, topicName=射血分数正常心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Aug 14 06:12:43 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994321, encodeId=220d199432164, content=<a href='/topic/show?id=b67646808b9' target=_blank style='color:#2F92EE;'>#射血分数正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46808, encryptionId=b67646808b9, topicName=射血分数正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Mar 02 11:12:43 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268689, encodeId=1a4e1268689dc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Nov 23 03:12:43 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072538, encodeId=debc10e253850, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Nov 21 16:34:18 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072528, encodeId=680010e25284c, content=好极了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00ed5697300, createdName=ms6000001024089719, createdTime=Sun Nov 21 16:06:05 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072487, encodeId=3f9e10e2487b9, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Nov 21 12:22:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696993, encodeId=5ea6169699325, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 19 04:12:43 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944298, encodeId=2bd419442984d, content=<a href='/topic/show?id=86a946809a5' target=_blank style='color:#2F92EE;'>#射血分数正常心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46809, encryptionId=86a946809a5, topicName=射血分数正常心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Aug 14 06:12:43 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994321, encodeId=220d199432164, content=<a href='/topic/show?id=b67646808b9' target=_blank style='color:#2F92EE;'>#射血分数正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46808, encryptionId=b67646808b9, topicName=射血分数正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Mar 02 11:12:43 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268689, encodeId=1a4e1268689dc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Nov 23 03:12:43 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072538, encodeId=debc10e253850, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Nov 21 16:34:18 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072528, encodeId=680010e25284c, content=好极了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00ed5697300, createdName=ms6000001024089719, createdTime=Sun Nov 21 16:06:05 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072487, encodeId=3f9e10e2487b9, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Nov 21 12:22:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696993, encodeId=5ea6169699325, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 19 04:12:43 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944298, encodeId=2bd419442984d, content=<a href='/topic/show?id=86a946809a5' target=_blank style='color:#2F92EE;'>#射血分数正常心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46809, encryptionId=86a946809a5, topicName=射血分数正常心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Aug 14 06:12:43 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994321, encodeId=220d199432164, content=<a href='/topic/show?id=b67646808b9' target=_blank style='color:#2F92EE;'>#射血分数正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46808, encryptionId=b67646808b9, topicName=射血分数正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Mar 02 11:12:43 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268689, encodeId=1a4e1268689dc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Nov 23 03:12:43 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072538, encodeId=debc10e253850, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Nov 21 16:34:18 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072528, encodeId=680010e25284c, content=好极了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00ed5697300, createdName=ms6000001024089719, createdTime=Sun Nov 21 16:06:05 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072487, encodeId=3f9e10e2487b9, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Nov 21 12:22:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
    2021-11-23 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=1696993, encodeId=5ea6169699325, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 19 04:12:43 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944298, encodeId=2bd419442984d, content=<a href='/topic/show?id=86a946809a5' target=_blank style='color:#2F92EE;'>#射血分数正常心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46809, encryptionId=86a946809a5, topicName=射血分数正常心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Aug 14 06:12:43 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994321, encodeId=220d199432164, content=<a href='/topic/show?id=b67646808b9' target=_blank style='color:#2F92EE;'>#射血分数正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46808, encryptionId=b67646808b9, topicName=射血分数正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Mar 02 11:12:43 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268689, encodeId=1a4e1268689dc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Nov 23 03:12:43 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072538, encodeId=debc10e253850, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Nov 21 16:34:18 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072528, encodeId=680010e25284c, content=好极了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00ed5697300, createdName=ms6000001024089719, createdTime=Sun Nov 21 16:06:05 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072487, encodeId=3f9e10e2487b9, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Nov 21 12:22:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
    2021-11-21 未来将来

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1696993, encodeId=5ea6169699325, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 19 04:12:43 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944298, encodeId=2bd419442984d, content=<a href='/topic/show?id=86a946809a5' target=_blank style='color:#2F92EE;'>#射血分数正常心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46809, encryptionId=86a946809a5, topicName=射血分数正常心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Aug 14 06:12:43 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994321, encodeId=220d199432164, content=<a href='/topic/show?id=b67646808b9' target=_blank style='color:#2F92EE;'>#射血分数正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46808, encryptionId=b67646808b9, topicName=射血分数正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Mar 02 11:12:43 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268689, encodeId=1a4e1268689dc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Nov 23 03:12:43 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072538, encodeId=debc10e253850, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Nov 21 16:34:18 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072528, encodeId=680010e25284c, content=好极了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00ed5697300, createdName=ms6000001024089719, createdTime=Sun Nov 21 16:06:05 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072487, encodeId=3f9e10e2487b9, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Nov 21 12:22:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
    2021-11-21 ms6000001024089719

    好极了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1696993, encodeId=5ea6169699325, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 19 04:12:43 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944298, encodeId=2bd419442984d, content=<a href='/topic/show?id=86a946809a5' target=_blank style='color:#2F92EE;'>#射血分数正常心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46809, encryptionId=86a946809a5, topicName=射血分数正常心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Sun Aug 14 06:12:43 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994321, encodeId=220d199432164, content=<a href='/topic/show?id=b67646808b9' target=_blank style='color:#2F92EE;'>#射血分数正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46808, encryptionId=b67646808b9, topicName=射血分数正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Mar 02 11:12:43 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268689, encodeId=1a4e1268689dc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Nov 23 03:12:43 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072538, encodeId=debc10e253850, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Nov 21 16:34:18 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072528, encodeId=680010e25284c, content=好极了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00ed5697300, createdName=ms6000001024089719, createdTime=Sun Nov 21 16:06:05 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072487, encodeId=3f9e10e2487b9, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Nov 21 12:22:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
    2021-11-21 SR~young海东

    坚持学习

    0

相关资讯

Front Cardiovasc Med :慢性阻塞性肺疾病患者的流感疫苗接种和室性心律失常风险:一项基于人群的纵向研究

流感疫苗接种可以降低慢性阻塞性肺疾病 (COPD) 患者发生主要心脏事件的风险。研究发现疫苗可降低此类患者发生室性心律失常 (VA)的风险。

Eur Heart J:房颤患者慢性阻塞性肺疾病的患病率、治疗和影响

COPD在AF患者中很常见,13%的AF患者伴有COPD,并且与合并症负担增加、差异化管理和更差的结局相关,全因死亡风险增加两倍以上,此外大出血和心血管死亡风险增加。

Front Pharmacol:评估慢性阻塞性肺疾病和阻塞性睡眠呼吸暂停综合征重叠综合征患者的长期预后

慢性阻塞性肺疾病 (COPD) 和阻塞性睡眠呼吸暂停 (OSAS) 重叠综合征 (OS) 患者被认为患心血管疾病的风险增加。OS 患者心血管疾病和 1 年死亡率的风险增加。

Eur Respir J:血液嗜酸性粒细胞计数和阻塞性肺疾病的关系

嗜酸性粒细胞计数与罹患OLD的风险呈正相关。该研究的结果表明,嗜酸性粒细胞计数可作为COPD发生发展的独立危险因素。

Respiratory Research:透明质酸对治疗慢性肺部疾病有效

研究人员发现吸入透明质酸可改善慢性阻塞性肺疾病(COPD)严重加重患者的肺功能。透明质酸是一种由活组织分泌的糖,作为细胞的支架,也被用作化妆品的皮肤润肤霜和鼻腔喷雾,以滋润肺部呼吸道。

AJRCCM:晚期肺动脉高压阻塞性肺功能的演变

肺动脉高压 (PAH) 的特征是肺动脉阻抗增加,导致运动不耐受和右心衰竭。 随着针对右心衰竭的治疗方法的改进,人们对 PAH 降低运动能力的新途径越来越感兴趣,这是一个关键的治疗目标。